As a physician-scientist and board-certified medical oncologist. I am devoted to the care of cancer patients in the clinic and to gaining knowledge in the laboratory of how cancers develop. My research focus is on the pathogenesis and treatment of prostate cancer. I am involved in a multidisciplinary effort with oncologists, pathologist, and surgeons to analyze tumor tissues and to develop clinical trials. My laboratory in the Human Oncology and Pathogenesis Program (HOPP) at Memorial Sloan Kettering Cancer Center focuses on the study of critical drivers in prostate cancer pathogenesis using cell, tissue, and mouse models.
- Clinical Expertise: Prostate Cancer; Bladder Cancer
- Languages Spoken: English
- Education: MD, Weill Cornell Medical College; PhD in Cell Biology, The Rockefeller University
- Residencies: Brigham and Women's Hospital
- Fellowships: Memorial Sloan Kettering Cancer Center
- Board Certifications: Internal Medicine, Medical Oncology
Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, Scardino PT, Rosen N, Sawyers CL.. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.. Cancer Cell 2011; 19 :575-86
Chen Y., Arora, V.K. Sawyers C.L. (2011). Molecular Biology of Prostate Cancer. In: Devita VT, Lawrence TS, Rosenberg SA, editors. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 9 ed. Philadelphia: Lippincott Williams & Wilkins.
Chi P, Chen Y, Zhang L, Guo X, Wongvipat J, Shamu T, Fletcher JA, Dewell S, Maki RG, Zheng D, Antonescu CR, Allis CD, Sawyers CL.. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature 2010; 467 :849-53
Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL.. Development of a second-generation antiandrogen for treatment of advanced prostate cancer.. Science 2009; 324 :787-90
Welsbie D, Xu J, Chen Y, Borsu L, Scher HI, Rosen N, Sawyers CL. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Research 2009; 69 :958-66
Chen Y, Sawyers CL. Molecular Biology of Prostate Cancer. In: DeVita VT, Lawrence TS, Rosenberg SA, editors. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology, 8th ed. Philadelphia: Lippincott Williams & Wilkins; 1385-91.
Ghia KK, Chen Y, Milner DA Jr, Fisher DC. Challenging manifestations of malignancies. Case 2. Langerhans cell histiocytosis presenting with a skin rash.. Journal of Clinical Oncology 2004; 22 :3640-3642
Rajagopal A, Pant AC, Simon SM, Chen Y.. In vivo analysis of human multidrug resistance protein 1 (MRP1) activity using transient expression of fluorescently tagged MRP1.. Cancer Research 2002; 62 :391-396
Altan N, Chen Y, Schindler M, Simon SM.. Tamoxifen inhibits acidification in cells independent of the estrogen receptor. . Proceedings of the National Academy of Sciences of the United States of America 1999; 96 :44432-4438
Chen Y, Gross P, Ramakrishna V, Rabitz H, Mease K, Singh H. Control of classical regime molecular objectives - applications of tracking and Variations of the theme. Automatica 1997; 33 :1617-1633
Chen Y., Gross P., Ramakrishn V., Rabitz H., Mease K., Singh H. Selective excitation of molecular eigenstates using state-dependent optical field design. Chemical Physics Letters 1996; 252 :447-456
Chen Y, Gross P, Ramakrishna V, Rabitz H., Mease K, Singh H. Competitive tracking of molecular objectives described by quantum mechanics. Journal of Chemical Physics 1995; 102 :8001-8010
As home to one of the world’s top cancer research centers, Memorial Sloan Kettering is typically involved in more than 900 clinical trials at a given time. Currently, clinical trials focused on the conditions I treat are enrolling new patients. If you’re interested in joining a clinical trial, click to learn about the trial’s purpose, eligibility criteria, and how to get more information.Learn more
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more